How to erase memory traces of pain and fear

Trends in Neurosciences

Volumn 36, Issue 6, 2013, Pages 343-352

  Sandkühler, Jürgen ^a   Lee, Jonathan ^b  

^a Medical University of Vienna   (Austria)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE A2 RECEPTOR AGONIST; AMPA RECEPTOR; MINOCYCLINE; PROTEIN KINASE; PROTEIN KINASE M ZETA; REMIFENTANIL; UNCLASSIFIED DRUG;

ALLODYNIA; AMNESIA; ANALGESIC ACTIVITY; ANOREXIA NERVOSA; ANXIETY; AVOIDANCE BEHAVIOR; CHRONIC PAIN; DRUG MEGADOSE; EXPLICIT MEMORY; FEAR; GLIA CELL; HUMAN; HYPERALGESIA; LONG TERM MEMORY; MEMORY; MEMORY CONSOLIDATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PAIN; PAIN THRESHOLD; PHOBIA; PRIORITY JOURNAL; PROCEDURAL MEMORY; RECOGNITION; REVIEW; SINGLE DRUG DOSE; TRANSCUTANEOUS NERVE STIMULATION;

ANALGESICS, OPIOID; ANIMALS; ANXIETY; CONDITIONING, CLASSICAL; CYCLOSERINE; EXTINCTION, PSYCHOLOGICAL; FEAR; HUMANS; HYPERALGESIA; ISOENZYMES; LONG-TERM POTENTIATION; MEMORY, LONG-TERM; MENTAL RECALL; MODELS, NEUROLOGICAL; MODELS, PSYCHOLOGICAL; NERVE TISSUE PROTEINS; NEUROGLIA; NOCICEPTION; PAIN; PAIN MANAGEMENT; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RATS; RECEPTORS, IONOTROPIC GLUTAMATE;

EID: 84878534617     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2013.03.004     Document Type: Review

References (122)

1. Blanchard R.J., Blanchard D.C. Crouching as an index of fear. J. Comp. Physiol. Psychol. 1969, 67:370-375.
2. Wilson H.D., et al. The relationship between basal level of anxiety and the affective response to inflammation. Physiol. Behav. 2007, 90:506-511.
3. Frot M., et al. Sex differences in pain perception and anxiety. A psychophysical study with topical capsaicin. Pain 2004, 108:230-236.
4. Keefe F.J., et al. Psychological aspects of persistent pain: current state of the science. J. Pain 2004, 5:195-211.
5. Rhudy J.L., Meagher M.W. Fear and anxiety: divergent effects on human pain thresholds. Pain 2000, 84:65-75.
6. LeDoux J.E. Emotion circuits in the brain. Annu. Rev. Neurosci. 2000, 23:155-184.
7. Fiddick L. There is more than the amygdala: potential threat assessment in the cingulate cortex. Neurosci. Biobehav. Rev. 2011, 35:1007-1018.
8. Sotres-Bayon F., Quirk G.J. Prefrontal control of fear: more than just extinction. Curr. Opin. Neurobiol. 2010, 20:231-235.
9. Rainville P. Brain mechanisms of pain affect and pain modulation. Curr. Opin. Neurobiol. 2002, 12:195-204.
10. Wiech K., et al. Neurocognitive aspects of pain perception. Trends Cogn. Sci. 2008, 12:306-313.
11. Staud R., et al. Brain activity related to temporal summation of C-fiber evoked pain. Pain 2007, 129:130-142.
12. Ploghaus A., et al. Dissociating pain from its anticipation in the human brain. Science 1999, 284:1979-1981.
13. Platon B., et al. High-frequency, high-intensity transcutaneous electrical nerve stimulation as treatment of pain after surgical abortion. Pain 2010, 148:114-119.
14. Sandkühler J. Long-lasting analgesia following TENS and acupuncture: spinal mechanisms beyond gate control. Proceedings of the 9th World Congress on Pain 2000, 359-369. IASP Press. M. Devor (Ed.).
15. Claydon L.S., et al. Dose-specific effects of transcutaneous electrical nerve stimulation (TENS) on experimental pain: a systematic review. Clin. J. Pain 2011, 27:635-647.
16. Dowswell T., et al. Transcutaneous electrical nerve stimulation (TENS) for pain relief in labour. Cochrane Database Syst. Rev. 2009, CD007214.
17. Sandkühler J. Models and mechanisms of hyperalgesia and allodynia. Physiol. Rev. 2009, 89:707-758.
18. Chu L.F., et al. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin. J. Pain 2008, 24:479-496.
19. Chang G., et al. Opioid tolerance and hyperalgesia. Med. Clin. North Am. 2007, 91:199-211.
20. Drdla R., et al. Induction of synaptic long-term potentiation after opioid withdrawal. Science 2009, 325:207-210.
21. Dableh L.J., et al. Neuropathic pain as a process: reversal of chronification in an animal model. J. Pain Res. 2011, 4:315-323.
22. Eaton M.J., et al. A single intrathecal injection of GABA permanently reverses neuropathic pain after nerve injury. Brain Res. 1999, 835:334-339.
23. Franklin M.E., Foa E.B. Treatment of obsessive compulsive disorder. Annu. Rev. Clin. Psychol. 2011, 7:229-243.
24. Strober M. Pathologic fear conditioning and anorexia nervosa: on the search for novel paradigms. Int. J. Eat. Disord. 2004, 35:504-508.
25. Sacco T., Sacchetti B. Role of secondary sensory cortices in emotional memory storage and retrieval in rats. Science 2010, 329:649-656.
26. Bouton M.E. Context and behavioral processes in extinction. Learn. Mem. 2004, 11:485-494.
27. Nader K., Hardt O. A single standard for memory: the case for reconsolidation. Nat. Rev. Neurosci. 2009, 10:224-234.
28. Lee J.L. Reconsolidation: maintaining memory relevance. Trends Neurosci. 2009, 32:413-420.
29. Drdla-Schutting R., et al. Erasure of a spinal memory trace of pain by a brief, high-dose opioid administration. Science 2012, 335:235-238.
30. Hu N-W., et al. Protein synthesis inhibition blocks the late-phase LTP of C-fiber evoked field potentials in rat spinal dorsal horn. J. Neurophysiol. 2003, 89:2354-2359.
31. Millecamps M., et al. D-cycloserine reduces neuropathic pain behavior through limbic NMDA-mediated circuitry. Pain 2007, 132:108-123.
32. Antal A., Paulus W. A case of refractory orofacial pain treated by transcranial direct current stimulation applied over hand motor area in combination with NMDA agonist drug intake. Brain Stimul. 2011, 4:117-121.
33. Millan M.J., Seguin L. Chemically-diverse ligands at the glycine B site coupled to N-methyl-D-aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice. Neurosci. Lett. 1994, 178:139-143.
34. Migues P.V., et al. PKMz maintains memories by regulating GluR2-dependent AMPA receptor trafficking. Nat. Neurosci. 2010, 13:630-634.
35. Shema R., et al. Rapid erasure of long-term memory associations in the cortex by an inhibitor of PKM z. Science 2007, 317:951-953.
36. Sacktor T.C. How does PKMz maintain long-term memory?. Nat. Rev. Neurosci. 2011, 12:9-15.
37. Kwapis J.L., et al. Protein kinase Mz maintains fear memory in the amygdala but not in the hippocampus. Behav. Neurosci. 2009, 123:844-850.
38. Parsons R.G., Davis M. Temporary disruption of fear-potentiated startle following PKMz inhibition in the amygdala. Nat. Neurosci. 2011, 14:295-296.
39. Marchand F., et al. Specific involvement of atypical PKCz/PKMz in spinal persistent nociceptive processing following peripheral inflammation in rat. Mol. Pain 2011, 7:86.
40. Laferrière A., et al. PKMz is essential for spinal plasticity underlying the maintenance of persistent pain. Mol. Pain 2011, 7:99.
41. Asiedu M.N., et al. Spinal protein kinase M z underlies the maintenance mechanism of persistent nociceptive sensitization. J. Neurosci. 2011, 31:6646-6653.
42. Li X-Y., et al. Alleviating neuropathic pain hypersensitivity by inhibiting PKMz in the anterior cingulate cortex. Science 2010, 330:1400-1404.
43. King T., et al. Contribution of PKMz-dependent and independent amplification to components of experimental neuropathic pain. Pain 2012, 153:1263-1273.
44. Gao Y-J., Ji R-R. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol. Ther. 2010, 126:56-68.
45. McMahon S.B., Malcangio M. Current challenges in glia-pain biology. Neuron 2009, 64:46-54.
46. Sandkühler, J. Spinal plasticity and pain. In Wall and Melzack's Textbook of Pain (6th edn) (Koltzenburg, M. and McMahon, S., eds), Elsevier Churchill Livingstone (in press).
47. Loram L.C., et al. Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain. J. Neurosci. 2009, 29:14015-14025.
48. Ledeboer A., et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 2005, 115:71-83.
49. Coull J.A.M., et al. Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature 2003, 424:938-942.
50. Coull J.A.M., et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 2005, 438:1017-1021.
51. Morgado C., et al. Minocycline completely reverses mechanical hyperalgesia in diabetic rats through microglia-induced changes in the expression of the potassium chloride co-transporter 2 (KCC2) at the spinal cord. Diabetes Obes. Metab. 2011, 13:150-159.
52. Sigurdsson T., et al. Long-term potentiation in the amygdala: a cellular mechanism of fear learning and memory. Neuropharmacology 2007, 52:215-227.
53. Maren S. Synaptic mechanisms of associative memory in the amygdala. Neuron 2005, 47:783-786.
54. Vaiva G., et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol. Psychiatry 2003, 54:947-949.
55. Pitman R.K., et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol. Psychiatry 2002, 51:189-192.
56. Holbrook T.L., et al. Morphine use after combat injury in Iraq and post-traumatic stress disorder. N. Engl. J. Med. 2010, 362:110-117.
57. Bryant R.A., et al. A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol. Psychiatry 2009, 65:438-440.
58. McGhee L.L., et al. The effect of propranolol on posttraumatic stress disorder in burned service members. J. Burn Care Res. 2009, 30:92-97.
59. Stein M.B., et al. Pharmacotherapy to prevent PTSD: results from a randomized controlled proof-of-concept trial in physically injured patients. J. Trauma Stress 2007, 20:923-932.
60. Serrano P., et al. Persistent phosphorylation by protein kinase M z maintains late-phase long-term potentiation. J. Neurosci. 2005, 25:1979-1984.
61. Pastalkova E., et al. Storage of spatial information by the maintenance mechanism of LTP. Science 2006, 313:1141-1144.
62. Serrano P., et al. PKMz maintains spatial, instrumental, and classically conditioned long-term memories. PLoS Biol. 2008, 6:2698-2706.
63. Sierra-Mercado D., et al. Dissociable roles of prelimbic and infralimbic cortices, ventral hippocampus, and basolateral amygdala in the expression and extinction of conditioned fear. Neuropsychopharmacology 2011, 36:529-538.
64. Volk L.J., et al. PKM-z is not required for hippocampal synaptic plasticity, learning and memory. Nature 2013, 493:420-423.
65. Yasumatsu N., et al. Principles of long-term dynamics of dendritic spines. J. Neurosci. 2008, 28:13592-13608.
66. Everitt B.J., et al. Appetitive behavior: impact of amygdala-dependent mechanisms of emotional learning. Ann. N. Y. Acad. Sci. 2003, 985:233-250.
67. Nader K., et al. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature 2000, 406:722-726.
68. Doyére V., et al. Synapse-specific reconsolidation of distinct fear memories in the lateral amygdala. Nat. Neurosci. 2007, 10:414-416.
69. Lee J.L., et al. Reconsolidation and extinction of conditioned fear: inhibition and potentiation. J. Neurosci. 2006, 26:10051-10056.
70. Debiec J., LeDoux J.E. Disruption of reconsolidation but not consolidation of auditory fear conditioning by noradrenergic blockade in the amygdala. Neuroscience 2004, 129:267-272.
71. Kindt M., et al. Beyond extinction: erasing human fear responses and preventing the return of fear. Nat. Neurosci. 2009, 12:256-258.
72. Brunet A., et al. Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials. J. Clin. Psychopharmacol. 2011, 31:547-550.
73. Monfils M.H., et al. Extinction-reconsolidation boundaries: key to persistent attenuation of fear memories. Science 2009, 324:951-955.
74. Schiller D., et al. Preventing the return of fear in humans using reconsolidation update mechanisms. Nature 2010, 463:49-53.
75. Kindt M., Soeter M. Reconsolidation in a human fear conditioning study: a test of extinction as updating mechanism. Biol. Psychol. 2011, 92:43-50.
76. Soeter M., Kindt M. Disrupting reconsolidation: pharmacological and behavioral manipulations. Learn. Mem. 2011, 18:357-366.
77. Martins I., et al. Reversal of neuropathic pain by HSV-1-mediated decrease of noradrenaline in a pain facilitatory area of the brain. Pain 2010, 151:137-145.
78. Lewis S.S., et al. (+)-Naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. J. Pain 2012, 13:498-506.
79. Zeilhofer H.U., et al. Fast synaptic inhibition in spinal sensory processing and pain control. Physiol. Rev. 2012, 92:193-235.
80. A receptor subtypes. Nature 2008, 451:330-334.
81. Abraham A.D., et al. Methylphenidate enhances extinction of contextual fear. Learn. Mem. 2012, 19:67-72.
82. Graham B.M., Richardson R. Fibroblast growth factor-2 enhances extinction and reduces renewal of conditioned fear. Neuropsychopharmacology 2010, 35:1348-1355.
83. Walker D.L., et al. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J. Neurosci. 2002, 22:2343-2351.
84. Ledgerwood L., et al. Effects of D-cycloserine on extinction of conditioned freezing. Behav. Neurosci. 2003, 117:341-349.
85. Ledgerwood L., et al. D-cycloserine and the facilitation of extinction of conditioned fear: consequences for reinstatement. Behav. Neurosci. 2004, 118:505-513.
86. Ressler K.J., et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch. Gen. Psychiatry 2004, 61:1136-1144.
87. Hofmann S.G., et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch. Gen. Psychiatry 2006, 63:298-304.
88. Guastella A.J., et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol. Psychiatry 2008, 63:544-549.
89. Otto M.W., et al. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol. Psychiatry 2010, 67:365-370.
90. Kushner M.G., et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol. Psychiatry 2007, 62:835-838.
91. Wilhelm S., et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am. J. Psychiatry 2008, 165:335-341.
92. Guastella A.J., et al. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J. Psychiatr. Res. 2007, 41:466-471.
93. Litz B.T., et al. A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J. Psychiatr. Res. 2012, 46:1184-1190.
94. de Kleine R.A., et al. A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol. Psychiatry 2012, 71:962-968.
95. Langton J.M., Richardson R. D-cycloserine facilitates extinction the first time but not the second time: an examination of the role of NMDA across the course of repeated extinction sessions. Neuropsychopharmacology 2008, 33:3096-3102.
96. Bliss T.V.P., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
97. Kerchner G.A., Nicoll R.A. Silent synapses and the emergence of a postsynaptic mechanism for LTP. Nat. Rev. Neurosci. 2008, 9:813-825.
98. Lisman J.E. The pre/post LTP debate. Neuron 2009, 63:281-284.
99. Schafe G.E., et al. Memory consolidation of Pavlovian fear conditioning: a cellular and molecular perspective. Trends Neurosci. 2001, 24:540-546.
100. Schafe G.E., LeDoux J.E. Memory consolidation of auditory pavlovian fear conditioning requires protein synthesis and protein kinase A in the amygdala. J. Neurosci. 2000, 20:RC96.
101. Nichols M.L., et al. Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science 1999, 286:1558-1561.
102. Zhuo M. Cortical plasticity as a new endpoint measurement for chronic pain. Mol. Pain 2011, 7:54.
103. Ikeda H., et al. Synaptic plasticity in spinal lamina I projection neurons that mediate hyperalgesia. Science 2003, 299:1237-1240.
104. Ikeda H., et al. Synaptic amplifier of inflammatory pain in the spinal dorsal horn. Science 2006, 312:1659-1662.
105. Bonicalzi V., Canavero S. Pharmacological treatment of neuropathic pain: present status and future directions. Therapy 2006, 3:651-677.
106. Zhou L-J., et al. Limited BDNF contributes to the failure of injury to skin afferents to produce a neuropathic pain condition. Pain 2010, 148:148-157.
107. Zhou L-J., et al. Brain-derived neurotrophic factor contributes to spinal long-term potentiation and mechanical hypersensitivity by activation of spinal microglia in rat. Brain Behav. Immun. 2011, 25:322-334.
108. 4 receptors and p38 MAPK in microglia. Glia 2009, 57:583-591.
109. Yang H-W., et al. Activation of spinal D1/D5 receptors induces late-phase LTP of c-fiber evoked field potentials in rat spinal dorsal horn. J. Neurophysiol. 2005, 94:961-967.
110. Ruscheweyh R., et al. Long-term potentiation in spinal nociceptive pathways as a novel target for pain therapy. Mol. Pain 2011, 7:20.
111. Wang Y., et al. Differential roles of phosphorylated AMPA receptor GluR1 subunits at Serine-831 and Serine-845 sites in spinal cord dorsal horn in a rat model of post-operative pain. Neurochem. Res. 2011, 36:170-176.
112. Luo C., et al. Presynaptically localized cyclic GMP-dependent protein kinase 1 Is a key determinant of spinal synaptic potentiation and pain hypersensitivity. PLoS Biol. 2012, 10:e1001283.
113. Romanski L.M., et al. Somatosensory and auditory convergence in the lateral nucleus of the amygdala. Behav. Neurosci. 1993, 107:444-450.
114. Clugnet M-C., LeDoux J.E. Synaptic plasticity in fear conditioning circuits: induction of LTP in the lateral nucleus of the amygdala by stimulation of the medial geniculate body. J. Neurosci. 1990, 10:2818-2824.
115. Doyère V., et al. Long-term potentiation in freely moving rats reveals asymmetries in thalamic and cortical inputs to the lateral amygdala. Eur. J. Neurosci. 2003, 17:2703-2715.
116. Apergis-Schoute A.M., et al. Auditory fear conditioning and long-term potentiation in the lateral amygdala require ERK/MAP kinase signaling in the auditory thalamus: a role for presynaptic plasticity in the fear system. J. Neurosci. 2005, 25:5730-5739.
117. Maren S., et al. Protein synthesis in the amygdala, but not the auditory thalamus, is required for consolidation of Pavlovian fear conditioning in rats. Eur. J. Neurosci. 2003, 18:3080-3088.
118. Bourtchouladze R., et al. Different training procedures recruit either one or two critical periods for contextual memory consolidation, each of which requires protein synthesis and PKA. Learn. Mem. 1998, 5:365-374.
119. Rudy J.W., Matus-Amat P. The ventral hippocampus supports a memory representation of context and contextual fear conditioning: implications for a unitary function of the hippocampus. Behav. Neurosci. 2005, 119:154-163.
120. Corcoran K.A., Quirk G.J. Activity in prelimbic cortex is necessary for the expression of learned, but not innate, fears. J. Neurosci. 2007, 27:840-844.
121. Schwienbacher I., et al. Temporary inactivation of the nucleus accumbens disrupts acquisition and expression of fear-potentiated startle in rats. Brain Res. 2004, 1027:87-93.
122. Sandkühler J., Gruber-Schoffnegger D. Hyperalgesia by synaptic long-term potentiation (LTP): an update. Curr. Opin. Pharmacol. 2011, 12:18-27.